Clinical Management and Outcomes of Lyme Disease in Wisconsin

D O’Leary, E Belongia, K Orloski, P Chyou, C Gale, M Finkel, E Hayes

United States Centers for Disease Control and Prevention, Fort Collins, CO

Marshfield Medical Research Foundation
Marshfield, WI

Mayo-Midelfort Clinic,
Eau Claire, WI
Background

- Lyme disease (LD)
  - Caused by spirochete *Borrelia burgdorferi*
  - Transmitted in US by *Ixodes scapularis* and *I. pacificus* ticks
  - Nationally-notifiable

  - (9.5 cases/100,000)

- Little is known regarding LD management practices and outcomes in the midwestern United States
Objectives

• Describe LD serologic testing and treatment in WI

• Identify temporal changes in clinical management of LD

• Assess clinical outcomes
Marshfield and / Mayo-Midelfort Clinic Network

• Marshfield Clinic
  – 450 physician multispecialty practice
  – regional centers in 31 central and northwest WI communities
  – fee-for-service and capitated care

• Mayo-Midelfort Clinic
  – multispecialty practice with >140 physicians
  – main campus in Eau Claire with regional centers in surrounding counties

• Representative of most ambulatory practice settings in WI
Methods: Case Ascertainment

- Clinical databases are linked between all outlying clinics and main clinic
- Databases include ICD-9 diagnoses on all patients
- Computerized search of diagnosis files between 1992-1998
- ICD-9 codes consistent with LD (088.81, 695.9, 066.9)
- Abstraction of corresponding medical charts
Medical Record Abstraction for LD-Related Illness

- Patient demographics
- Signs and symptoms
- Diagnostic testing
- Treatment
- Clinical outcomes
National LD Surveillance Case Definition

• Clinical criteria
  • Erythema migrans, or
  • At least one late manifestation and laboratory confirmation of infection

• Laboratory criteria for diagnosis
  • Isolation of *Borrelia burgdorferi* from clinical specimen, or
  • Demonstration of diagnostic levels of IgM or IgG antibodies to the spirochete in serum or CSF, or
  • A significant change in antibody levels in paired acute and convalescent serum samples
LD Case Classification

- **Probable (EM or Late LD)**
  - Met national surveillance case definition for EM or late LD

- **Possible (EM or Late LD)**
  - EM documented but size ≤ 5cm or unspecified
  - Positive LD serologic test with recurrent arthralgias or neurologic manifestations not meeting the probable case definition

- **Not LD**
  - Illness meeting neither of above criteria
Outcome Classification

- Medical record reviewed up to three years after initial visit to ascertain clinical outcome
  - 'complete resolution'
    - No mention of LD at last clinic visit
  - 'persistent LD symptoms'
    - LD mentioned at last clinic visit
  - 'insufficient information'
    - No follow-up after initial clinic visit
Results: Patient Classification

N = 1,180

Not LD
569 (48%)

LD*
611 (52%)

EM
407 (67%)

Late LD
204 (33%)

Probable EM
300 (74%)

Possible EM
107 (26%)

Probable Late LD
68 (33%)

Possible Late
136 (67%)

*All LD patients: 56% male; median age = 37
Frequency of Serologic Testing Among Patients With EM

Probable EM: 236/300 (79%) tested
Possible EM: 73/107 (68%) tested
Frequency of Serologic Testing Among Patients With Late LD

![Serologic Testing Graph]

- **Probable Late LD:** 67/68 (99%) tested
- **Possible Late LD:** 136/136 (100%) tested
Proportion of Patients with ≥4 Serologic Tests

<table>
<thead>
<tr>
<th>Patient classification</th>
<th>Year of diagnosis</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1992-95</td>
<td>1996-98</td>
</tr>
<tr>
<td>Probable EM</td>
<td>12%</td>
<td>13%</td>
</tr>
<tr>
<td>Probable Late LD</td>
<td>52%</td>
<td>34%</td>
</tr>
<tr>
<td>Not LD</td>
<td>9%</td>
<td>22%</td>
</tr>
</tbody>
</table>
Antimicrobial Use

- The most frequently prescribed antimicrobials for initial therapy:
  - Doxycycline
  - Amoxicillin
  - Ceftriaxone

- Patients without LD:
  - 94% received antimicrobials
  - 29% received multiple courses

- No temporal changes in proportion of patients receiving multiple courses of antimicrobials
Clinical Outcomes

Probable EM
Possible EM
Probable Late LD
Possible Late LD
Not LD

- Insufficient Information / Not Reported
- Persistent Symptoms
- Complete Resolution
Limitations

- Study based on medical record abstraction
  - Visits possibly missed due to patients seeking care in other systems
  - Inconsistent documentation of signs and symptoms in medical records
  - Variation in scheduled patient follow-up
  - Temporal changes in accepted testing methods
Conclusions

• Serologic testing was common among patients with EM
  – empiric therapy recommended (Ann Int Med 1997; 127, 1106-1108)

• There was a temporal increase in patients without LD who had ≥4 serologic tests
  – Decreasing number of tests for patients with late LD

• Recommended drugs are used for LD therapy (Clin Inf Dis 2000; 31, Supp. 1, S1-S14)
  – but they are often given to patients without LD

• The majority of patients have complete resolution of LD symptoms
Conclusions

- Serologic testing was common among patients with EM
  - empiric therapy recommended (Ann Int Med 1997; 127, 1106-1108)

- There was a temporal increase in patients without LD who had ≥4 serologic tests
  - Decreasing number of tests for patients with late LD

- Recommended drugs are used for LD therapy (Clin Inf Dis 2000; 31, Supp. 1, S1-S14)
  - but they are often given to patients without LD

- The majority of patients have complete resolution of LD symptoms
Acknowledgements

• Marshfield Clinic
  – Catherine Grimm
  – Nita Herr
  – Deborah Hilgemann
  – Deborah Kempf
  – Donna Wittman
  – Sonia Weigel
  – Lorelle Ziegelbauer

• Mayo-Midelfort Clinic
  – Londa Dahnke
  – Peggy Munden
  – Robert Noyce, MD
## Patient Demographic Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Not LD</th>
<th>EM</th>
<th>Late LD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (median)</strong></td>
<td>41 years</td>
<td>36 years</td>
<td>41 years</td>
</tr>
<tr>
<td><strong>% Male</strong></td>
<td>51%</td>
<td>56%</td>
<td>60%</td>
</tr>
</tbody>
</table>
### Multiple-course (≥2) Antimicrobial Therapy: Temporal Analysis

<table>
<thead>
<tr>
<th>Patient classification</th>
<th>Year of diagnosis</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1992-95</td>
<td>1996-98</td>
</tr>
<tr>
<td>Probable EM</td>
<td>19%</td>
<td>13%</td>
</tr>
<tr>
<td>All EM</td>
<td>21%</td>
<td>14%</td>
</tr>
<tr>
<td>Probable Late LD</td>
<td>63%</td>
<td>57%</td>
</tr>
<tr>
<td>All Late LD</td>
<td>53%</td>
<td>56%</td>
</tr>
<tr>
<td>Not LD</td>
<td>28%</td>
<td>31%</td>
</tr>
</tbody>
</table>
Late manifestations of LD

- **Musculoskeletal System:** Recurrent, brief attacks of objective joint swelling in or a few joints.
- **Nervous System:** Lymphocytic meningitis, cranial neuritis (especially facial palsy), radiculoneuropathy or, rarely encephalomyelitis alone or in combination.
- **Cardiovascular System:** Acute onset, high grade (2\textsuperscript{nd} or 3\textsuperscript{rd} degree) atrioventricular defects that resolve in days or weeks and are sometimes associated with myocarditis.
Comparision of Results With Other Studies

• Published studies from other endemic settings
  – MC Reid et.al., 1998: New England
  – LH Sigal et.al., 1990: Mid-Atlantic
Demographic Characteristics of Patients with EM

<table>
<thead>
<tr>
<th></th>
<th>Probable EM</th>
<th>Possible EM</th>
<th>All EM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median)</td>
<td>36 years</td>
<td>41 years</td>
<td>38 years</td>
</tr>
<tr>
<td>% Male</td>
<td>56%</td>
<td>59%</td>
<td>57%</td>
</tr>
</tbody>
</table>
Demographic Characteristics of Patients with Late LD

<table>
<thead>
<tr>
<th></th>
<th>Probable Late LD</th>
<th>Possible Late LD</th>
<th>All Late LD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median)</td>
<td>41 years</td>
<td>37 years</td>
<td>37 years</td>
</tr>
<tr>
<td>% Male</td>
<td>40%</td>
<td>52%</td>
<td>48%</td>
</tr>
</tbody>
</table>
Serologic Tests Performed for Patients With Late LD

(n = 404 tests)

- EIA: 50%
- Western Blot (IgM): 25%
- Western Blot (IgG): 15%
- IFA (IgM): 7%
- IFA (IgG): 3%

3%
### Proportion of Patients Receiving Any Antimicrobial Therapy

<table>
<thead>
<tr>
<th>Patient Classification</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>All EM (n=407)</td>
<td>99%</td>
</tr>
<tr>
<td>All Late LD (n=204)</td>
<td>99%</td>
</tr>
<tr>
<td>Not LD (n=569)</td>
<td>94%</td>
</tr>
</tbody>
</table>